News

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a…

1 year ago

ARCPOINT INC. ANNOUNCES ACCELERATED RELEASE OF LOCK-UP SHARES TO INCREASE TRADING LIQUIDITY OF SHARES

Greenville, South Carolina, March 17, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV:ARC) (the “Company” or “ARCpoint”), announces accelerated release of…

1 year ago

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2023

Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2023 (Pursuant to Article L.233-8 II of the…

1 year ago

Eargo to Report Fourth Quarter 2022 Financial Results on March 23, 2023

SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission…

1 year ago

Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Big Sky, Montana

MINNEAPOLIS, MN, US, March 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")…

1 year ago

Better Choice’s Halo Pet Food Brand Awarded “2022 Consumer’s Favorite Imported Cat Brand” by the China Pet Industry White Paper

After polling over 30,000 pet owners in China, Halo was voted as one of the top picks in the imported…

1 year ago

CancerVax Universal Cancer Vaccine Being Developed by UCLA

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny,…

1 year ago

Healthcare Integrated Technologies, Inc. Announces Approval of U.S. Patent for Fall Validation with Privacy-Aware Monitoring System

Knoxville, Tennessee, March 17, 2023 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leading innovator of healthcare technology solutions,…

1 year ago

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®…

1 year ago

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®Marketing…

1 year ago